Windlas Biotech Ltd. benchmarking: Performance to industry peers

Financial

	Windlas Biotech	Beta Drugs	Hester Biosciences
Operational Metrics
Financials
5 yr Average ROE	10.64 %	22.74 %	10.99 %
5yr average Equity Multiplier	1.39	1.82	2.14
5yr Average Asset Turnover Ratio	1.07	1.03	0.46
5yr Avg Net Profit Margin	7.49 %	12.23 %	11.57 %
Price to Book	2.88	6.68	4.61
P/E	25.2	39.44	29.85
5yr Avg Cash Conversion Cycle	-12.87 Days	7.75 Days	60.38 Days
Inventory Days	39.91 Days	46.07 Days	100.79 Days
Days Receivable	72.81 Days	91.57 Days	89.02 Days
Days Payable	93.99 Days	119.03 Days	127.62 Days
5yr Average Interest Coverage Ratio	42.87	14.42	6.96
5yr Avg ROCE	16.39 %	27.84 %	11.14 %
5yr Avg Operating Profit Margin	12.11 %	21.76 %	22.71 %
5 yr average Debt to Equity	0.05	0.29	0.75
5yr CAGR Net Profit	30.97 %	29.34 %	-4.4 %
5yr Average Return on Assets	7.71 %	12.69 %	5.28 %
Shareholdings
Promoter Holding	61.9 %	64.63 %	53.73 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-0.48 %	-2.1 %	0.0
Change in Mutual Fund Holding (3 Yrs)	-3.56 %	0.0	0.0

	Windlas Biotech	Beta Drugs	Hester Biosciences
Product Wise Break-Up	Product Wise Break-Up CDMO 71.67 Trade Generics & OTC 22.75 Exports 5.58 Manufacturing of Oncology medicines 0 Animal Healthcare 0 Poultry Healthcare 0	Product Wise Break-Up Exports 0 Animal Healthcare 0 Poultry Healthcare 0 CDMO 0 Trade Generics & OTC 0 Oncology 100.0	Product Wise Break-Up Exports 0 Animal Health 35.36 Poultry Healthcare 64.64 CDMO 0 Trade Generics & OTC 0 Manufacturing of Oncology medicines 0
Location Wise Break-Up	Location Wise Break-Up India 95.68 Rest of the World 0 Africa 0 Nepal 0 India 0 Others 4.32	Location Wise Break-Up Rest of the World 0 India 0 Nepal 0 Africa 0 Others 100	Location Wise Break-Up Rest of the World 9.0 India 91.0 Nepal 0 Africa 0
Acute vs Chronic	Acute vs Chronic Chronic & Sub-Chronic 59.0 Acute 41.0	-	-
Segment Wise Break-Up	Segment Wise Break-Up Pharmaceutical 100.0	-	-